Non-Compacted Cardiomyopathy: Is there a Need of a New Cardiomyopathy?

Francesco Bianco1,2*, Piergiusto Vitulli1, Valentina Bucciarelli1, Alvin Chandra1,2, Masatoshi Minamisawa2,3 and Sabina Gallina1

1Institute of Cardiology, Chieti, Italy
2Brigham and Women’s Hospital, Boston, USA
3Department of Cardiovascular Medicine, Matsumoto, Japan

*Corresponding author: Francesco Bianco, Institute of Cardiology, Chieti, Italy

Received: April 04, 2019
Published: April 09, 2019

ISSN: 2638-5368

Abstract

Left ventricular non-compaction (LVNC) is a myocardial disorder, classically defined as a double-layered myocardium, consisting of a thick and spongy/hypertrabeculated, non-compacted endocardial segment and a thin and compacted, epicardial portion. The American Heart Association (AHA) classifies LVNC as a distinct primary genetic cardiomyopathy, while the European Association of Cardiology (ESC) as an unclassified cardiomyopathy. Despite the magnitude of the entire literature yield on this topic, to date the pathogenesis, prognosis, and treatment are still unclear. Prevalence and mortality can range respectively from 0.05% to 0.26% and 5% to 47%, but they are affected by the imaging criteria adopted for the diagnosis. In fact, LVNC has been for years incidentally discovered during autopsy of unexplained sudden cardiac deaths. Conversely, with the advent of increasingly sophisticated cardiac imaging techniques, the presence of hypertrabeculated myocardium has become very common. Both echocardiographic and magnetic resonance criteria have been proven to overestimate the diagnosis, which shares a peculiar phenotype with other pathologies. It is known that a hypertrabeculated left ventricle leads to a symptomatic triad consisting of heart failure, arrhythmias and thromboembolisms. Therefore, it is current opinion of the authors that a “non-compaction cardiomyopathy” (NC-CMP) seems to be the most comprehensive definition of a disease that, similarly to the other cardiomyopathies, and regardless of its etiology, beyond a peculiar phenotype shares a distinct symptomatology and deserves to be listed as an entity between cardiomyopathies.

Keywords: Left Ventricle Non-Compaction; Non-Compacted Cardiomyopathy; Cardiomyopathies; Heart Failure; Sudden Cardiac Death

Introduction

Left ventricular non-compaction (LVNC) is a myocardial disorder, classically defined as a double-layered myocardium, consisting of a thick and spongy or hypertrabeculated endocardial segment, defined as non-compacted, and a thin and compacted portion, laying epicardially [1]. The above-mentioned hypertrabeculations (HXTs) characteristically involve the left ventricle (LV), especially the apex, the lateral, infero-lateral and inferior wall [1,2], and less frequently the right ventricle [3]. Since its first reports, LVNC has always been considered a controversial pathology (Figures 1 & 2). In facts Grant and colleagues, for long accredited as discoverers in 1926, presented a case of persistent sinusoids instead of LVNC [1]. In addition, a lack of uniqueness among the World Health Organization [4], the European Society of Cardiology [5], and the American Heart Association [6] for its classification, and the presence of trabeculae as a terminal phenotype of LV hemodynamic overload or other myocardial affections, has led several authors to debate on the real existence of a true form of uncomplicated primitive non-compacted cardiomyopathy [7,8].
Morpho Pathogenesis

The primitive hypothesis concerning LVNC is that the presence of HTXs is due to a failure in myocardial morphogenesis, in which the immature, non-compacted fetal myocardium normally undergoes a physiological compaction process during ontogenesis [1]. LVNC may occur isolated, in familial forms or associated with several congenital, genetic, neuromuscular and chromosomal conditions [9]. Mutations in the sarcomere gene, particular in MYH7, are the most common and non- sarcomere gene mutations (such as TAZ and NOTCH1) have also reported [10-12]. Some LVNC individuals have been detected by tracking asymptomatic relatives of affected patients [9], and therefore, a close correlation between genotype and phenotype has been recently underlined by 2 recent studies using NEXT-generation sequencing [13,14]. All these pathogenic variants were independent risk factors for cardiovascular events [13]. In addition, mutations in hyperpolarization-activated cyclic nucleotide channel 4 (HCN4) have also been reported in families with sinus node dysfunction and LVNC [15,16].

Epidemiology

Since only few studies focused on LVNC incidence, both prevalence and mortality are challenging to assess [1]. Among adults, it can be diagnosed in 0.05% - 0.26% of the cases, and approximately 0.14% of pediatric patient, with an overall mortality ranging from 5% to 47% in both populations [1]. Unfortunately, all the reports are affected by the diagnostic criteria adopted, imaging or autopsies, overestimating or underestimating the real prevalence.
In addition, and similarly with others cardiomyopathies, LVNC can be a subtle disease [17]; if not promptly diagnosed, patients may be asymptomatic for a long time and the onset may range from the early life to the adulthood [8].

**Diagnosis**

The advent of increasingly sophisticated cardiac imaging techniques set the spotlight on HXTs as a very common finding, instead of the rare disease that was previously considered [2,18,19]. Accordingly, Jenni, Chin and Stollberg defined different echocardiographic criteria, while Petersen, Jacquier, Captur and Stacey defined some cardiovascular magnetic resonance (CMR) criteria. 1 Unfortunately, they both showed very poor specificity [7,8], even if CMR overcame the ultrasound-related limits in morphologic assessment, and demonstrated a high correlation between late gadolinium enhancement myocardial fibrosis and clinical severity of the disease [20]. Nevertheless, there still a lack of an imaging-driven diagnostic gold standard [1,9].

**Clinical Aspects and Treatment**

Clinical findings are variable, including several grades of diastolic and systolic dysfunction, heart failure (HF), thromboembolic events, and malignant arrhythmias. 1 However, the most severe outcome is the sudden cardiac death. Atrial fibrillation, right/left bundle branch block, and repolarization abnormalities may be the only electrocardiographic features present at the moment of the diagnosis [2,8]. There is no specific therapy and LVNC management depends on the clinical manifestations; anticoagulation is indicated only if atrial fibrillation, heart failure, previous embolism, or intracardiac thrombus formation are present [1,21].

**Discussion**

LVNC has always been a controversial disease, with some unresolved issues. First of all, there is a heterogeneous genetic background and a wide spectrum of associated conditions that may occur contextually with HTxs. Secondly, LVNC real prevalence is still unknown. Certainly, the lack of any echocardiographic or CMR diagnostic gold standard, with frequent overestimation/underestimation, does not help to clarify all the uncertainties. In addition, there are a wide variety of overlapping conditions that may occur with secondary myocardial HXTs, for example, a dilated cardiomyopathy or the end-stage hypertrophic cardiomyopathy (Figure 3). On the other hand, it is common experience that not all the above-mentioned cardiomyopathies and conditions can present an end-stage non-compacted phenotype and generalizing this aspect would be very simplistic. 8 In addition, Lorca and colleagues recently reiterated that non-compacted forms of cardiomyopathy do exist, especially during early stages of life, and they can be demonstrated in some forms of unexplained sudden deaths. 17 Furthermore, a multicenter longitudinal prospective study [7], despite its conclusions, and if carefully read between the lines, suggests that a significant proportion of asymptomatic patients meets all currently used imaging diagnostic criteria for LVNC.

Figure 3: Cardiac magnetic resonance imaging (CMR) exams of patients matching the currently imaging criteria for CMR (A, B, C, 2-chambers view; a, b, c, 4chambers view). (A, a) A 23-years-old male patients with a dilated cardiomyopathy. (B, b) a 38-years old woman with an end-stage hypertrophic cardiomyopathy. (C, c) a 45-years old woman admitted in emergency room for acute heart failure, and history of silent cerebral infarcts.

However, they demonstrated that outcomes are increased by symptoms and clinical conditions when associated with a non-compacted phenotype. Indeed, a recently published multicenter register provided an accurate estimation of genetic-phenotype association, and clinical and events of LVNC patients, concluding that the clinical course of symptomatic LVNC patient with a genotype-phenotype matching can be severe [13,14]. Given all these premises, it is reasonable considering the existence of a primitive non-compacted disease, congenital and a mild form, with a late-onset, and/or acquired conditions. HF, thromboembolic
Non-Compacted Cardiomyopathy: Is there a Need of a New

event, and malignant arrhythmias seem to constitute the clinical
trial for LVNC patients, and sudden cardiac death the most
severe outcome. There is a tight genotype-phenotype correlation,
with a wide spectrum of genes and mutation involved, as well
as hypertrophic cardiomyopathy, for example, and the current
imaging-derived diagnostic criteria probably need to be revised;
perhaps it should be worth to combine some imaging and clinical
criteria. At last, multicentric registries should be considered to
help the real prevalence assessment of non-compacted forms of
cardiomyopathies.

Conclusion

It is current opinion of the authors that a “non-compacted
cardiomyopathy” (NC-CMP) seems to be the most comprehensive
definition of a disease that, similarly to the other cardiomyopathies,
and regardless of its etiology, beyond a peculiar phenotype shares
a distinct symptomatology and deserves to be listed as an entity
between cardiomyopathies.

References

1. Finsterer J, Stollberger C, Towbin JA (2017) Left ventricular
noncompaction cardiomyopathy: cardiac, neuromuscular, and genetic
factors. Nat Rev Cardiol 14(4): 224-237.
2. Stollberger C, Finsterer J (2004) Left ventricular hypertro- 
phication/ noncompaction. Journal of the American Society of
echocardiography 17(1): 91-100.
3. Stacey RB, Andersen M, Haag J, Hall ME, McLeod G, et al. (2014) Right
ventricular morphology and systolic function in left ventricular
noncompaction cardiomyopathy. Am J Cardiol 113(6): 1018-1023.
4. (1996) Report of the 1995 World Health Organization/International
Society and Federation of Cardiology Task Force on the Definition
and Classification of Cardiomyopathies. Circulation 93(5): 841-842.
5. Elliott P, Andersson B, Arbustini E, Bilińska Z, Cecchi F (2008)
Classification of the cardiomyopathies: a position statement from the
European Society of Cardiology Working Group on Myocardial and
Pericardial Diseases. Eur Heart J 29(2): 270-276.
6. Mann BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, et al. (2006)
Contemporary definitions and classification of the cardiomyopathies:
an American Heart Association Scientific Statement from the Council
on Clinical Cardiology, Heart Failure and Transplantation Committee;
Quality of Care and Outcomes Research and Functional Genomics and
Translational Biology Interdisciplinary Working Groups; and Council on
Epidemiology and Prevention. Circulation 113(14): 1807-1816.
7. Andreini D, Pontone G, Bogaert J, Roghi A, Barison A, et al. (2016) Long-
Term Prognostic Value of Cardiac Magnetic Resonance in Left Ventricle
Noncompaction: A Prospective Multicenter Study. J Am Coll Cardiol
68(20): 2166-2181.
8. Weir-McCall JR, Yeap PM, Papagiorcopolou C, Fitzgerald K, Gandy SJ, et
al. (2016) Left Ventricular Noncompaction: Anatomical Phenotype or
Distinct Cardiomyopathy? J Am Coll Cardiol 68(20): 2157-2165.
9. Ikeda U, Minamisawa M, Koyama J (2015) Isolated left ventricular non-
compaction cardiomyopathy in adults. J Cardiol 65(S): 91-97.
10. Ichida F, Tsubata S, Bowles KR, Haneda N, Uese K, et al. (2001) Novel Gene
Mutations in Patients With Left Ventricular Noncompaction or Barth
Syndrome. Circulation 103(9): 1256-1263.
11. Lucan G, Casanova JC, Martinez-Poveda B, Prados B, D'Amato G, et al.
(2013) Mutations in the NOTCH pathway regulator MIB1 cause left
ventricular non-compaction cardiomyopathy. Nat Med 19(2): 193-201.
12. Van Waning JJ, Caliskan K, Hoedemaekers YM, van Spaadonck-Zwartz
KY, Baae AF, et al. (2018) Clinical Features, and Long-Term Outcome
of Noncompaction Cardiomyopathy. J Am Coll Cardiol 71(7): 711-722.
13. Sedaghat Hamedani F, Haas J, Zhu F, Geier C, Kayvanpour E, et al. (2017)
Clinical genetics and outcome of left ventricular non-compaction
cardiomyopathy. Eur Heart J 38(46): 3449-3460.
14. Wang C, Hata Y, Hinono K, Takasaki A, Ozawa SW, et al. (2017) A Wide
and Specific Spectrum of Genetic Variants and Genotype-Phenotype
Correlations Revealed by Next-Generation Sequencing in Patients with
Left Ventricular Noncompaction. J Am Heart Assoc 6(9).
15. Milano A, Vermeer AM, Lodder EM, Barc J, Verkerk AO (2014) HCN4
mutations in multiple families with bradycardia and left ventricular
noncompaction cardiomyopathy. J Am Coll Cardiol 64(7): 745-756.
16. Schweizer PA, Schroeter J, Greiner S, Haas J, Yamпольский P, et al. (2014)
The symptom complex of familial sinus node dysfunction and myocardial
noncompaction is associated with mutations in the HCN4 channel. J Am
Coll Cardiol 64(8): 757-767.
17. Lorca R, Martín M, Reguero JJ, Díaz-Molina B, Moris C, Lambert JL,
Astdillo A (2016) Left ventricle non-compaction: The still misdiagnosed
cardiomyopathy. Int J Cardiol 223: 420-421.
18. Duncan RF, Brown MA, Worley SG (2008) Increasing identification of
isolated left ventricular non-compaction with cardiovascular magnetic
resonance: a mini case series highlighting variable clinical presentation.
Heart Lung Circ 17(1): 9-13.
19. Sandhu R, Finkelhor RS, Gunawardena DR, Bahler RC (2008) Prevalence
and characteristics of left ventricular noncompaction in a community
hospital cohort of patients with systolic dysfunction. Echocardiography
25(1): 8-12.
20. Nucofaro G, Aquaro GD, Pingitore A, Masci PG, Lombardi M (2011)
Myocardial fibrosis in isolated left ventricular non-compaction and its
relation to disease severity. Eur J Heart Fail 13(2): 170-176.
21. Arbustini E, Favalli V, Narula N, Serio A, Grassi M (2016) Left Ventricular
Noncompaction: A Distinct Genetic Cardiomyopathy? J Am Coll Cardiol
68(9): 949-966.

Advancements in Cardiovascular Research

Assets of Publishing with us

- Global archiving of articles
- Immediate, unrestricted online access
- Rigorous Peer Review Process
- Authors Retain Copyrights
- Unique DOI for all articles

Citation: Francesco B, Piergiusto V, Valentina B, Alvin C, Masatoshi M, et al., Non-Compacted Cardiomyopathy: Is there a Need of a New
Cardiomyopathy? Adv Card Res 2(1)-2019. ACR.MS.ID.000129. DOI: 10.32474/ACR.2019.02.000129.